Vildagliptin as add‐on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus1. (May 2016)

• Record Type: Journal Article
• Authors: Ning, Guang; Wang, Weiqing; Li, Ling; Ma, Jianhua; Lv, Xiaofeng; Yang, Ming; Wang, Wei; Woloschak, Michael; Lukashevich, Valentina; Kothny, Wolfgang
• Is Part Of: Journal of diabetes. Volume 8:Number 3(2016:May)
• Page Start: 345
• Page End: 353
• Publication Date: 2016-05
• Subjects: add‐on insulin -- dipeptidyl peptidase‐4 -- type 2 diabetes mellitus -- vildagliptin; 胰岛素基础上添加治疗 -- 二肽基肽酶‐4 -- 2型糖尿病 -- 维格列汀; Diabetes -- Periodicals; 618.3646005
• DOI: 10.1111/1753-0407.12303
• Languages: English
• ISSNs: 1753-0393

Abstract

Abstract: Background: The aim of the present study was to investigate the efficacy and safety of vildagliptin added onto insulin with or without metformin in an Asian, predominantly Chinese, population with type 2 diabetes mellitus (T2DM). Methods: In this 24‐week, multicenter, double‐blind, placebo‐controlled trial, patients with T2DM inadequately controlled (HbA1c 7.5%–11.0%) on stable therapy with long‐acting, intermediate‐acting, or premixed insulin, with or without concomitant metformin, were randomized to receive vildagliptin 50 mg b.i.d. or placebo. Results: Of 293 patients randomized, 146 received vildagliptin and 147 received placebo treatment. At baseline, the overall mean age of patients was 58.1 years, mean T2DM duration was 11.3 years, and mean HbA1c was 8.7%. The adjusted mean (±SE) change in HbA1c at Week 24 in the vildagliptin and placebo groups was −1.08 ± 0.12% and −0.38 ± 0.12%, respectively (between‐treatment difference −0.70 ± 0.16%; P < 0.001). The between‐group difference in fasting plasma glucose was −0.43 ± 0.38 mmol/L ( P = 0.259). Significantly, more patients achieved HbA1c <7.0% with vildagliptin than with placebo (23.6% vs 11.2%; P = 0.006). The incidence of adverse events in the vildagliptin and placebo groups was 43.8% and 46.3%, whereas that of serious adverse events was 3.4% and 6.8%, respectively. The frequency of hypoglycemia was lower in the vildagliptin than placebo group (2.7% vs 5.4%). Conclusion: The addition of vildagliptin 50 mg b.i.d. significantly improved glycemic control without an increased risk of hypoglycemia in Asian, predominantly Chinese, patients with T2DM inadequately controlled on insulin, with or without metformin.